Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:MTNB OTCMKTS:PVOTF NASDAQ:TPST NYSEAMERICAN:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTNBMatinas Biopharma$0.79-1.4%$0.62$0.48▼$3.09$5.12M1.67383,618 shs24,528 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsTPSTTempest Therapeutics$1.27-2.3%$1.78$1.23▼$12.23$19.25M-1.85120,466 shs103,760 shsVNRXVolitionRX$1.79-10.5%$2.90$1.75▼$18.80$17.25M1.04268,891 shs454,019 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTNBMatinas Biopharma+2.83%+0.69%+22.89%+33.11%-3.63%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%TPSTTempest Therapeutics+2.36%-24.86%-39.53%-43.72%-81.13%VNRXVolitionRX-3.85%-30.56%-14.16%-49.52%-82.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTNBMatinas Biopharma$0.79-1.4%$0.62$0.48▼$3.09$5.12M1.67383,618 shs24,528 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsTPSTTempest Therapeutics$1.27-2.3%$1.78$1.23▼$12.23$19.25M-1.85120,466 shs103,760 shsVNRXVolitionRX$1.79-10.5%$2.90$1.75▼$18.80$17.25M1.04268,891 shs454,019 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTNBMatinas Biopharma+2.83%+0.69%+22.89%+33.11%-3.63%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%TPSTTempest Therapeutics+2.36%-24.86%-39.53%-43.72%-81.13%VNRXVolitionRX-3.85%-30.56%-14.16%-49.52%-82.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTNBMatinas Biopharma 0.00N/AN/AN/APVOTFBetterLife Pharma 0.00N/AN/AN/ATPSTTempest Therapeutics 1.50ReduceN/AN/AVNRXVolitionRX 2.50Moderate Buy$46.672,530.59% UpsideCurrent Analyst Ratings BreakdownLatest MTNB, VNRX, PVOTF, and TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026VNRXVolitionRX BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/20/2026VNRXVolitionRX CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold4/20/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/2/2026VNRXVolitionRX HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $20.003/26/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.003/18/2026VNRXVolitionRX D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTNBMatinas Biopharma$1.10M4.55N/AN/A$0.75 per share1.04PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AVNRXVolitionRX$1.73M8.85N/AN/A($5.30) per share-0.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTNBMatinas Biopharma-$10.35M-$3.89N/AN/AN/AN/A-193.02%-124.09%N/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ATPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)VNRXVolitionRX-$23.36M-$0.56N/AN/AN/A-997.49%N/A-289.87%8/13/2026 (Estimated)Latest MTNB, VNRX, PVOTF, and TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/14/2026Q1 2026VNRXVolitionRX-$0.70-$0.97-$0.27-$0.97$1.52 million$0.99 million5/8/2026Q1 2026MTNBMatinas BiopharmaN/A-$0.30N/A-$0.30N/AN/A3/31/2026Q4 2025MTNBMatinas BiopharmaN/A-$0.26N/A-$0.26N/AN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMTNBMatinas BiopharmaN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTNBMatinas BiopharmaN/A1.321.32PVOTFBetterLife PharmaN/A3.623.62TPSTTempest TherapeuticsN/A0.740.74VNRXVolitionRXN/A0.330.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTNBMatinas Biopharma11.77%PVOTFBetterLife PharmaN/ATPSTTempest Therapeutics22.52%VNRXVolitionRX8.09%Insider OwnershipCompanyInsider OwnershipMTNBMatinas Biopharma4.60%PVOTFBetterLife Pharma34.77%TPSTTempest Therapeutics6.28%VNRXVolitionRX8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMTNBMatinas Biopharma306.41 million6.11 millionN/APVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableTPSTTempest Therapeutics2014.81 million13.88 millionNo DataVNRXVolitionRX808.63 million7.61 millionNot OptionableMTNB, VNRX, PVOTF, and TPST HeadlinesRecent News About These CompaniesVolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringJune 3 at 8:12 AM | prnewswire.comVolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsMay 27, 2026 | prnewswire.comVolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | finance.yahoo.comVolitionRX Earnings Call Balances Breakthroughs and RisksMay 20, 2026 | tipranks.comVolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...May 15, 2026 | finance.yahoo.comVolitionRX Earnings Call: Breakthrough Science, Cash Burn RiskMay 15, 2026 | tipranks.comVolitionRx Limited (VNRX) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comVolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 | prnewswire.comVolitionRx (VNRX) price target increased by 1,618.09% to 29.79May 14, 2026 | msn.comVolitionRX Ltd.May 12, 2026 | marketwatch.comVolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11, 2026 | prnewswire.comVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 | prnewswire.comVolitionRx Enacts One-for-Twenty Reverse Stock SplitApril 29, 2026 | theglobeandmail.comVolition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingApril 29, 2026 | prnewswire.comVolitionRx (VNRX) price target decreased by 17.48% to 1.73April 28, 2026 | msn.comVNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1 ...April 28, 2026 | finance.yahoo.comVolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanApril 23, 2026 | prnewswire.comD Boral Capital downgrades VolitionRx (VNRX)April 21, 2026 | msn.comVolition Launches rNuQ™ Webshop Broadening Product RangeApril 20, 2026 | prnewswire.comVolitionRx Earnings Call: Breakthroughs Amid Funding StrainApril 4, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTNB, VNRX, PVOTF, and TPST Company DescriptionsMatinas Biopharma NYSEAMERICAN:MTNB$0.79 -0.01 (-1.38%) As of 04:10 PM EasternMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Tempest Therapeutics NASDAQ:TPST$1.27 -0.03 (-2.31%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.03 (+2.28%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.VolitionRX NYSEAMERICAN:VNRX$1.79 -0.21 (-10.50%) Closing price 04:10 PM EasternExtended Trading$1.68 -0.11 (-6.31%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
